All of Us Research Program
Do you want to change the future of health? The Froedtert & MCW health network is part of the National Institutes of Health All of Us Research Program. It has a simple mission — speed up health research breakthroughs. To do this, All of Us is asking one million people to share their health information. Learn how you can help make a difference by joining the All of Us Research Program.
120 results for "Cancer" and "Endocrine Cancers"
A Randomized Phase III Trial of Olanzapine Versus Megestrol Acetate for Cancer-Associated Anorexia
Olanzapine vs Megestrol Acetate for the Treatment of Loss of Appetite Among Advanced Cancer Patients
Protocol No
ALLIANCE-A222004-ANOREXIA
Gilead-GS-US-546-5920: A Phase 2 Multi-Arm Study of Magrolimab Combinations in Patients with Myeloid Malignancies
Magrolimab Combinations in Patients with Myeloid Malignancies
Protocol No
GILEAD-GS-US-546-5920
Sub Category
A Multisite, Phase II Study of Isatuximab, Pomalidomide, Elotuzumab and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma
Isatuximab, Pomalidomide, Elotuzumab and Dexamethasone in Relapsed and/or Refractory MM
Protocol No
IIT-DHAKAL-IMPEDE-SGZ-12356
Sub Category
A Phase 1b/2 Study Of AVB-S6-500 In Combination with Cabozantinib, AVB-S6-500 In Combination with Cabozantinib and Nivolumab, and AVB-S6-500 Monotherapy in Patients with Advanced or Metastatic Clear Cell Renal Cell Carcinoma
Safety and Efficacy Study of AVB-S6-500 in Patients With Advanced Clear Cell Renal Cell Carcinoma
Protocol No
ARAVIVE-AVB500-RCC-003
Sub Category
A Randomized Phase 2 Study Of Erdafitinib Versus Investigator Choice Of Intravesical Chemotherapy In Subjects Who Received Bacillus Calmette-Guérin (BCG) And Recurred With High Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) And FGFR Mutations Or Fusions
Erdafitinib vs Investigator Choice of Intravesical Chemo for NMIBC Pts Who Recurred After BCG
Protocol No
JANSSEN-42756493BLC2003-THOR-2
Sub Category
High Dose Re-Irradiation Utilizing Advanced Defromable Image Registration (DIR) and Individualized Organ At Risk (OAR) Dose Calculations with Organ Specific Toxicity Analysis (Re-DIRICT)
A Phase II study of Re-Irradiation Utilizing DIR and OAR Dose Calculations with Organ Specific Toxicity Analysis
Protocol No
IIT-GORE-REDIRICT
Phase III Trial of Immunotherapy-Based Combination Therapy with or Without Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma (Probe Trial)
Immunotherapy-Based Drug Combo w wo Surgery to Remove Kidney in Mets Kidney Cancer
Protocol No
SWOG-S1931-PROBE-TRIAL
Sub Category
A Phase 1, Open-Label, Dose-Escalation, and Dose-Expansion Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of SRK-181 Administered Alone or in Combination with a Checkpoint Inhibitor in Patients with Locally Advanced or Metastatic Solid Tumors (Dragon)
Evaluate the safety and tolerability of single-agent SRK-181 and determine the maximum tolerated dose (MTD) or maximum administered dose (MAD) and evaluate dose-limiting toxicities (DLTs) of single-agent SRK-181.
Protocol No
SCHOLARROCK-SRK-181-001
STEEL: A Randomized Phase II Trial of Salvage Radiotherapy with Standard vs Enhanced Androgen Deprivation Therapy (with Enzalutamide) in Patients with Post-Prostatectomy PSA Recurrences with Aggressive Disease Features
Salvage Radiotherapy w or w/o Enzalutamide in Recurrent Prostate Cancer Following Surgery
Protocol No
RTOG-FND-3506-STEEL
Sub Category
An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 Combined with a Tyrosine Kinase Inhibitor (TKI) in Patients with Relapsed or Refractory Ph+ Chronic Myeloid Leukemia (CML)
KRT-232 and TKI Study in Chronic Myeloid Leukemia
Protocol No
KARTOS-KRT-232-117-CML
Sub Category
A Phase 2, Open-label Study to Evaluate the Safety and Efficacy of MK-7684A (MK-7684 [Vibostolimab] with MK-3475 [Pembrolizumab] Coformulation) in Participants with Relapsed or Refractory Hematological Malignancies
Vibostolimab with Pembrolizumab in Relapsed or Refractory Hematological Malignancies
Protocol No
MERCK-MK-7684A-004
Sub Category
A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Birtamimab Plus Standard of Care vs. Placebo Plus Standard of Care in Mayo Stage IV Subjects with Light Chain (AL) Amyloidosis
Birtamimab plus SOC vs Placebo plus SOC in Mayo Stage IV Subjects with Light Chain (AL) Amyloidosis
Protocol No
PROTHENA-NEOD001-301
Sub Category
A Phase II Study of Ruxolitinib for Bronchiolitis Obliterans Syndrome (BOS) after Allogeneic Hematopoietic Cell Transplantation (HCT)
A Phase II Study of Ruxolitinib for Bronchiolitis Obliterans Syndrome (BOS) after AlloHCT
Protocol No
DF-HCC-18-265-BOS
Sub Category
An Open Label, Multi-Center Phase IIIb Study Of Asciminib (ABL001) Monotherapy In Previously Treated Patients With Chronic Myeloid Leukemia In Chronic Phase (CML-CP) With And Without T315I Mutation (AIM4CML)
ABL001 in Previously Treated CML-CP With or Without T315I Mutation
Protocol No
NOVARTIS-CABL001AUS04-AIM4CML
Sub Category
A Phase 1, Multi-Center, Open-Label, Dose Finding Study Of CC-92328 In Subjects With Relapsed and/or Refractory Multiple Myeloma
To determine the safety and tolerability of CC-92328 in subjects with R/R MM. To define the maximum tolerated dose (MTD) and/or the recommended Phase 2 dose (RP2D) of CC-92328 in subjects with R/R MM.
Protocol No
CELGENE-CC-92328-MM-001
GILEAD-5F9009-MDS: ENHANCE: A Randomized, Double-blind, Multicenter Study Comparing Magrolimab in Combination with Azacitidine versus Azacitidine Plus Placebo in Treatment-naïve Patients with Higher Risk MDS
Magrolimab + Azacitidine versus Azacitidine + Placebo in Untreated MDS
Protocol No
FORTYSEVEN-5F9009-MDS
Sub Category
A Single-arm, Open-label, Phase 1 Study Evaluating the Safety, Efficacy, and Cellular Kinetics/Pharmacodynamics of ALLO-715 and ALLO-647 to Evaluate an Anti-BMCA Allogeneic CAR T Cell Therapy with or without Nirogacestat in Patients with Relapsed/Refractory Multiple Myeloma
Phase 1 Study of ALLO-715, an antiBCMA Allo CAR-T cell therapy for pt with rrMM
Protocol No
ALLOGENE-ALLO-715-101-RRMM
Sub Category
A Single-Arm, Open-Label, Phase 1/2 Study Evaluating the Safety, Efficacy, and Cellular Kinetics/Pharmacodynamics of Allo-501A and Anti-CD19 Allogeneic CAR-T Cell Therapy, and ALLO-647, an Anti-CD52 Monoclonal Antibody in Subjects with Relapsed/Refractory Large B-Cell Lymphoma (LBCL)
Safety and Efficacy of ALLO-501 Anti-CD19 Allogeneic CAR-T Cells in Adults with rr LBCL
Protocol No
ALLOGENE-ALLO-501A-201
Sub Category
Asciminib As Initial Therapy For Patients With Chronic Myeloid Leukemia In Chronic Phase
Asciminib As Initial Therapy For Patients With Chronic Myeloid Leukemia In Chronic Phase
Protocol No
HJKC3-0004
Sub Category
Phase 1/2 Study Of REGN4336 (A PSMAXCD3 Bispecific Antibody) Administered Alone Or In Combination With Cemiplimab In Patients With Metastatic Castration-Resistant Prostate Cancer
To assess the safety, tolerability, and PK and to determine RP2DR of REGN4336
separately as monotherapy or in combination with cemiplimab.
separately as monotherapy or in combination with cemiplimab.
Protocol No
REGENERON-R4336-ONC-20104
A Phase 1, Open-Label, Multicenter Study of HMPL-306 in Advanced Hematological Malignancies with Isocitrate Dehydrogenase (IDH) Mutations
To evaluate the safety and tolerability of HMPL-306 in patients with advanced hematological malignancies that harbor IDH mutations and characterize safety and tolerability to determine RP2D of HMPL-306 in patients with advanced hematological malignancies that harbor IDH mutations.
Protocol No
HMP-2020-306-GLOB1